Velusetrag Patent for Chronic Intestinal Pseudo-Obstruction Treatment

ChangeBridge: EPO Bulletin - Pharma (A61K)

Published March 18th, 2026

Detected March 24th, 2026

Summary

The European Patent Office has published patent application EP4590303A1 for Alfasigma S.p.A. concerning the use of Velusetrag for treating chronic intestinal pseudo-obstruction. This patent is designated for multiple European states.

View original document View source feed page

What changed

The European Patent Office (EPO) has published patent application EP4590303A1, filed by Alfasigma S.p.A., detailing the use of Velusetrag for the treatment of chronic intestinal pseudo-obstruction (CIPO). The publication date is March 18, 2026, and the patent is designated for numerous European states including Germany, France, and the United Kingdom.

This patent publication represents a new intellectual property filing related to a specific pharmaceutical treatment. For compliance officers in the pharmaceutical sector, this indicates a potential new therapeutic development by Alfasigma S.p.A. While this is a patent publication and not a regulatory rule, it may inform competitive intelligence and R&D strategies. No immediate compliance actions are required based solely on this patent publication.

Source document (simplified)

← EPO Patent Bulletin

VELUSETRAG FOR USE IN THE TREATMENT OF CHRONIC INTESTINAL PSEUDO-OBSTRUCTION (CIPO)

Publication EP4590303A1 Kind: A1 Mar 18, 2026

Applicants

Alfasigma S.p.A.

Inventors

VESCI, Loredana, GRIMALDI, Maria, GIORGI, Fabrizio, GIOVANNINI, Roberto, BARONE, Michelangelo

IPC Classifications

A61K 31/4709 20060101AFI20240329BHEP A61P 1/00 20060101ALI20240329BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →